Peptide-oligonucleotide conjugates form stable and selective complexes with antibody and DNA.
The present work demonstrates that the relatively low molecular weight synthetic peptide-oligonucleotide conjugates are capable of stable and selective three-component complex formation with complementary 72-100mer DNA oligonucleotides and a cardiac troponin I monoclonal antibody. Neither the Watson-Crick-type interaction between peptide-oligonucleotide conjugate and DNA nor the conjugate-antibody interaction dramatically hampers the other. These interactions remain selective and specific in the presence of several other conjugates not specific to cardiac troponin I monoclonal antibody as well as in the presence of control 100mer DNA oligonucleotides. The data herein demonstrate the feasibility of the synthetic peptide-oligonucleotide conjugates as convenient molecular tools, e.g., for antibody epitope mapping.
Department of Pharmaceutical Chemistry, University of Kuopio, FIN-70211 Kuopio, Finland.
Tuula
T
Tennilä
Maxim
M
Antopolsky
Alex
A
Azhayev
Elena
E
Azhayeva
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000918:Antibody Specificity; D000941:Antigens / Q000276:immunology; D020029:Base Pairing; D001483:Base Sequence; D004247:DNA / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D005240:Feasibility Studies; D008969:Molecular Sequence Data; D009841:Oligonucleotides / Q000737:chemistry / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D010455:Peptides / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism*; D011485:Protein Binding; D013379:Substrate Specificity
D000911:Antibodies, Monoclonal; D000941:Antigens; D009841:Oligonucleotides; D010455:Peptides; D004247:DNA